Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Summary

NIMBLE is a prospective study for blood biomarker study of lung nodules alongside analysing data which has been collected routinely as part of patient care. The primary aim of NIMBLE is to assess whether artificial intelligence and machine learning based radiomics approaches can be used to distinguish between benign disease and malignancy in a new lung nodule after a previously treated cancer, and where malignant to differentiate between metastatic recurrence or a new primary lung cancer.

Conditions

• Lung Cancer

Sponsors & Collaborators

• Royal Brompton & Harefield NHS Foundation Trust

  collaborator OTHER

• Royal Marsden Partners West London Cancer Alliance

  collaborator UNKNOWN

• Imperial College London

  collaborator OTHER

• University College London Hospitals

  collaborator OTHER

• Lewisham and Greenwich NHS Trust

  collaborator OTHER_GOV

• Guy's and St Thomas' NHS Foundation Trust

  collaborator OTHER

• Epsom and St Helier University Hospitals NHS Trust

  collaborator OTHER

• King's College Hospital NHS Trust

  collaborator OTHER

• University College London (UCL) Cancer Institute

  collaborator OTHER

• Institute of Cancer Research, United Kingdom

  collaborator OTHER

• Francis Crick Institute

  collaborator OTHER

• Royal Sussex County Hospital

  collaborator OTHER

• Royal Marsden NHS Foundation Trust

  lead OTHER

Principal Investigators

• Richard Lee, Dr · The Royal Marsden Hospitals NHS Trust

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-07

Primary Completion

2026-01-01

Completion

2031-01-01

Countries

• United Kingdom

Study Locations